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was safety regarding hematological and gastrointestinal 
toxicity grade III/IV, secondary endpoints were other tox-
icities, clinical benefit rate (CBR), time to progression 
(TTP), overall survival (OS) and quality of life.
Results 250 patients were treated with treosulfan i.v. (128) 
or treosulfan p.o. (122). In general treosulfan therapy was 
well tolerated in both treatment arms. Leukopenia grade 
III/IV occurred significantly more frequently in the p.o. 
arm (3.9% i.v. arm, 14.8% p.o. arm, p = 0.002). Other 
toxicities were similar in both arms. CBR was comparable 
between arms (41.4% i.v. arm, 36.9% p.o. arm). No differ-
ence in TTP (3.7 months i.v. arm, 3.5 months p.o. arm) or 
OS (13.6 months i.v. arm, 10.4 months p.o. arm, p = 0.087) 
occurred.
Conclusions Given the safety and efficacy results treo-
sulfan is an acceptable option for heavily pretreated OC 
patients. Regarding the toxicity profile the i.v. application 
was better tolerated with less grade III and IV toxicities.
Keywords Treosulfan · Oral versus intravenous · Ovarian 
cancer · Recurrent
Abstract 
Objective In recurrent ovarian cancer (ROC), there is a 
high demand on effective therapies with a mild toxicity 
profile. Treosulfan is an alkylating agent approved as oral 
(p.o.) and intravenous (i.v.) formulation for the treatment 
of recurrent ovarian cancer. Data on safety and efficacy for 
either formulation are rare. For the first time we conducted 
a randomized phase III study comparing both formulations 
in women with ROC.
Methods Patients having received at least two previous 
lines of chemotherapy were randomly assigned to one of 
two treatment arms: treosulfan i.v. 7000 mg/m2 d1 q4w or 
treosulfan p.o. 600 mg/m2 d1-28 q8w. Primary endpoint 
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Introduction
In Europe, ovarian cancer is the fifth most common can-
cer and one of the five leading malignancies responsible 
for cancer-related deaths among females (Ferlay et al. 
2013). As the results of EUROCARE-5 study demon-
strated the European mean age-standardized 5-year sur-
vival for ovarian cancer is low-37.6% (De Angelis et al. 
2014). About 66,000 women in Europe were diagnosed 
with ovarian cancer and estimated 42,000 died of this 
disease in 2012 (Ferlay et al. 2013). Primary treatment 
of ovarian cancer includes cytoreductive surgery fol-
lowed by systemic chemotherapy. Standard first-line 
chemotherapy is based on platinum and taxanes—eventu-
ally in combination with bevacizumab—which achieves 
high response rates up to 80% (McGuire et al. 1996; 
Pujade-Lauraine et al. 2010). However, in the major-
ity of patients the disease recurs and further therapy is 
required. Drug-resistance to platinum-based chemother-
apy is one of the most difficult clinical situations because 
the effect of the current therapies is very limited and the 
outcome is poor. There is a need for implementation of 
new chemotherapeutic agents for further treatment. Treo-
sulfan (Ovastat®) is a bifunctional prodrug of an alkylat-
ing cytotoxic agent that is licensed in several European 
countries for the treatment of ROC (Gropp et al. 1998; 
Hilger et al. 2000). Treosulfan also shows activity in 
other solid tumors and hematologic malignancies (Boz-
tug et al. 2014; Köpf-Maier and Sass 1996). It is known 
for its modest toxicity profile as demonstrated in previ-
ous phase II and III studies (Reed et al. 2006; Kledsen 
et al. 1998). With a relative bioavailability of 97%, treo-
sulfan p.o. has shown a nearly equivalent bioavailability 
(AUCoral = 82.1 ± 39.4 µg/ml h) compared to treosul-
fan i.v. (AUCi.v. = 85.4 ± 30.3 µg/ml h) in ovarian can-
cer patients (Hilger et al. 2000). Till now data on safety 
and efficacy for either formulation in heavily pretreated 
patients with ovarian cancer are rare. Therefore, for the 
very first time, we conducted a randomized phase IIIb 
study comparing the intravenous versus oral formulation 
of treosulfan in women with recurrent ovarian cancer.
Patients and methods
This open label, randomized, controlled, multicenter phase 
IIIb trial was conducted at 30 institutions in Germany. 
Patients were eligible for enrollment, if they had histologi-
cally confirmed ROC and had received at least two previ-
ous lines of chemotherapy. After inclusion of 18 patients an 
amendment inured, stating that induction and re-induction 
of platinum-containing pretreatments were counted as one 
treatment line. A further amendment was implemented after 
the inclusion of 85 patients stating that also patients with 
more than two previous treatment lines could be included, 
and induction and re-induction therapy were counted as 
separate treatment lines. For data analysis, induction and 
re-induction therapy lines were counted as one therapy line. 
Written informed consent was given by all patients before 
enrollment. For patient inclusion following criteria needed 
to be met: (1) two-dimensional measurable tumor lesion or 
progressive disease evaluable by increased CA125 (>100 
U/ml); (2) life expectancy of at least 3 months; (3) Kar-
nofsky index >50%; (4) adequate organ functions, defined 
as leukocyte count ≥3.5 cells × 109/l, platelet count 
≥100 × 109/l, creatinine and total bilirubin 1.25 × the 
upper limit of the normal range or less; (5) no prior treat-
ment with treosulfan; (6) no second malignancy (except 
basilioma or cervical cancer in situ); (7) no ascites/pleural 
effusion without evaluable or measurable tumor lesion or 
not elevated CA125; (8) no concurrent radiotherapy or anti-
neoplastic therapy.
Patients were randomly assigned to one of the two treat-
ment arms: treosulfan i.v. 7000 mg/m2 d1 q4w or treosulfan 
p.o. 600 mg/m2 d1-28 q8w. Treatment was continued until 
tumor progression, unacceptable toxicity or treatment delay 
for more than 2 weeks. Patients with a complete remis-
sion received optional chemotherapy for two more months 
before therapy was terminated. Supportive care was allowed 
and given individually according to clinical requirements. 
Patients in both arms needed to have a leukocyte count of at 
least 3500 cells/µl and a platelet count of at least 100,000/
µl to receive subsequent cycles of chemotherapy. Treosul-
fan dose had to be reduced for 1000 mg/m2 body surface 
for i. v. administration or one capsule for oral administra-
tion in the next treatment cycle, if leukocytes dropped 
below 1000 cells/µl or platelets dropped below 25,000/µl 
upon administration of treosulfan. Re-escalation was not 
allowed. For patients with renal insufficiency receiving 
treosulfan i.v., treatment-dose was reduced to 6000 mg/m2, 
if creatinine clearance was 20–40 ml/min and to 5000 mg/
m2 if creatinine clearance was less than 20 ml/min. The pri-
mary endpoint of the study was the comparison of safety 
of both schemes regarding hematological and gastrointesti-
nal toxicity grade III and IV. Adverse events were assessed 
continuously by patient questioning, physical examination 
and evaluation of laboratory results, and graded according 
to the National Cancer Institute Common Toxicity criteria 
(CTC) version 2.0. Secondary endpoints were comparison 
of other adverse events, clinical benefit rate (CBR), time 
to progression (TTP), overall survival (OS) and quality of 
life. Response was evaluated by assessment of two-dimen-
sional measurable lesions and determination of CA125 lev-
els. Lesions were examined every 3 months using imaging 
procedures. CA125 levels were determined every month. A 
complete response was defined as complete disappearance 
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of tumor lesions. A partial response was defined as 50% or 
more decrease in tumor size. Assessments had to be con-
firmed after at least 4 weeks. No change/stable disease 
was defined as less than 50% decrease or less than 25% 
increase in tumor size or of reference metastasis. Progres-
sive disease was defined as appearance of any new lesions 
or growth of more than 25% or increase in CA125 level by 
more than 25%. This increase had to be confirmed after at 
least 2 weeks. TTP was defined as the time from the date of 
randomization to the date of first documented progression. 
Patients not experiencing PD were censored with the last 
date of either tumor evaluation, measurement of CA125 
or with the start of a new therapy. Survival was defined as 
the time from date of therapy start to date of death. Patients 
who were alive at the end of the study were censored at 
the last date where they were known to be alive. Platinum-
sensitivity was defined by a relapse-free period of more 
than 6 months following platinum-based chemotherapy. 
Platinum-sensitivity was calculated using the relapse-free 
interval from end of the last platinum-containing therapy 
until start of the following therapy (Hanker et al. 2012). For 
the analyses of treatment duration, every cycle started was 
calculated as a full cycle. Quality of life was assessed using 
the EORTC QLQ-C30 questionnaire. Patients were asked 
to complete the questionnaire before first cycle of study 
therapy and consecutively during treatment every other 
month. The last questionnaire was completed at the end of 
treatment visit. Once patients discontinued therapy because 
of complete remission or intolerable toxicity, disease sta-
tus was assessed every 3 months. After disease progression 
follow-up was only performed on survival data.
Statistical analysis
The sample size was planned to detect a 15% difference 
in the incidence of grade 3/4 adverse events of hemato-
logical or gastrointestinal origin between the two treat-
ment arms. An event was assumed to occur with a prob-
ability of 25%. Calculation was based on a two-sided test 
with α = 0.05 and 80% power. As no clear hypothesis was 
stated, all p values are explorative. There was no adjust-
ment for multiple testing. A total number of 270 patients 
(129 per treatment arm plus 4% dropouts) were planned 
to be recruited. All analyses were based on the safety 
population including all patients who received at least one 
dose of study medication. Differences in proportions of 
adverse events and response were analyzed using a two-
sided Fisher’s exact test or two-sided χ2 test. Clinical ben-
efit rate (CBR) was defined as sum of complete remission 
(CR), partial remission (PR) and no change (NC) as best 
response (CBR = CR + PR + NC). Time to progression 
(TTP) and overall survival time (OS) were estimated by 
use of Kaplan–Meier, and differences were compared using 
the log-rank test. Subgroup analyses were performed ret-
rospectively. Hazard ratios were calculated using cox and 
logistic models. Effects of possible confounders were esti-
mated using multivariate cox or logistic regression mod-
eling. For the calculation of quality of life scores, scoring 
manuals were applied. All analyses were performed using 
STATISTICA version 10 or R 2.15.1.
Results
Patient characteristics
Between November 2002 and January 2014, 265 patients 
were enrolled at 30 study sites. Patient consort diagram is 
shown in Fig. 1. 250 patients (128 treosulfan i.v. and 122 
treosulfan p.o.) received at least one dose of treosulfan 
and were evaluable (safety set). Patient characteristics are 
shown in Table 1. There were no substantial differences 
between both treatment arms. Patients received two previ-
ous chemotherapies in median. As first-line therapy 82% of 
patients received a platinum-containing regimen combined 
with paclitaxel. As second-line therapy topotecan or a plat-
inum-containing regimen were administered in about 45% 
of patients. The median number of concomitant diseases 
was three. Most important concomitant diseases are listed 
in Table 1.
Treatment
The mean number of administered treatment cycles was 
4.4 (95% CI 3.7–5.1; median 3.0) in the i.v. arm and 2.3 
(95% CI 1.9–2.8; median 2.0) in the p.o. arm. Consider-
ing that i.v. and p.o. treatment cycles are of different length 
(28 days for the i.v. arm and 56 days for the p.o. arm) treat-
ment duration was comparable in both treatment arms. 64% 
(160 of 250) of patients continued study treatment until dis-
ease progression as scheduled in the protocol. Unforeseen 
treatment discontinuations were limited and comparable 
in both treatment arms (27.3% in the i.v. arm and 30.3% 
in the p.o. arm). The proportion of discontinuations due to 
toxicity was significantly higher in the p.o. treatment arm 
(17.2%) than in the i.v. treatment arm (6.3%; p = 0.0094) 
(Fig. 1). The median dose intensity in the i.v. arm was 
97.8% (25–75% quartile, 90.0–100.8%) and 99.6% on the 
p.o. arm (25–75% quartile, 84.0–124.4%).
Adverse events/toxicity
Adverse events occurred in 91.2% of patients (90.6% in the 
i.v. arm and 91.8% in the p.o. arm). Toxicities of grade III/
IV were rare. 25.0 and 30.3% of patients in the i.v. and p.o. 
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arm experienced serious adverse events, respectively. Fre-
quently reported hematological and non-hematological tox-
icities of all grades are listed in Table 2. Hematological and 
gastrointestinal toxicities were the main grade III/IV toxici-
ties and were observed in 17.6% (12.5% in the i.v. arm and 
22.1% in the p.o. arm) and 18.0% (17.9% in the i.v. arm 
and 18.0% in the p.o. arm) of patients, respectively. The 
severity of hematological events differed between treatment 
arms. Although the total number of reported hematological 
events of all grades was similar in both arms (40.6% in the 
i.v treatment arm, 39.3% in the p.o. treatment arm), grade 
III/IV events occurred more often in the p.o. arm (22.1% 
vs.12.5% in the i.v. arm). The frequency of grade III/IV 
leukopenia was significantly higher in the p.o. treatment 
arm than in the i.v. arm (14.8% in the p.o. arm and 3.9% 
in the i.v. arm, p = 0.0038). However, only one patient in 
the p.o. arm experienced a febrile neutropenia grade III. In 
addition to hematological and gastrointestinal toxicities, 
constitutional symptoms and pain were recorded most fre-
quently. Alopecia occurred in 19 (7.6%) of patients. Almost 
all cases were grade I events, only one patient suffered from 
alopecia grade II. No grade III alopecia occurred. Except 
the above mentioned, no differences in hematological and 
non-hematological toxicities of any grade between both 
arms were observed. 17 patients (11 in the i.v. arm and 6 
in the p.o. arm) died during study period. In all cases, death 
was concerned as not related to study medication. Underly-
ing malignant disease was stated as cause of death for ten 
patients in the i.v. arm and five patients in the p.o. arm. Two 
patients, one in the i.v arm and one in the p.o. arm died 
of thromboembolic events (pulmonary embolism in the p.o. 
arm and stroke in the i.v. arm) not considered to be caused 
by the study medication.
Efficacy
Response was evaluable in 212 patients (111 in the i.v. arm 
and 101 in the p.o. arm). Non-evaluable patients mainly 
resulted from early treatment discontinuations, when no 
response assessment was performed. CBR was 39.2% 
(95% CI 33.2–45.6) and was comparable between both 
arms (treosulfan i.v.: 41.4, 95% CI 32.9–50.5; treosulfan 
Fig. 1  CONSORT diagram. 
i.v., intravenous; p.o., per os/
oral
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p.o.: 36.9, 95% CI 28.5–46.1; p = 0.6063) (Table 3). The 
median follow-up was 8.6 months (10.0 months in the i.v. 
arm and 7.6 months in the p.o. arm). We could not detect 
any significant difference in the median TTP and median 
OS between both treatment arms (Figs. 2a, 3a). However, 
a nonsignificant trend toward longer survival in the i.v. arm 
was observed. Median TTP was 3.7 months (95% CI 2.9–
4.8) in the i.v. treatment arm and 3.5 months (95% CI 2.8–
4.4) in the p.o. treatment arm (Fig. 2a; HR 1.07, 95% CI 
0.81–1.41, p = 0.634). Median OS was 13.6 months (95% 
CI 11.3–16.8) in the i.v. treatment arm and 10.4 months 
(95% CI 8.6–12.8) in the p.o. treatment arm (Fig. 2b; HR 
1.28, 95% CI 0.96.1.70, p = 0.0873).
Subgroup analyses on efficacy parameters were per-
formed using three models, each of them exploring the 
impact of the following covariates on CBR, TTP and OS: 
route of administration (p.o. vs. i.v.), platinum-sensitivity 
(platinum-sensitive vs. platinum-resistant), number of 
previous therapy lines (>2 lines vs. ≤2 lines) and Karnof-
sky index (<90 vs. ≥90) (S1 A-C). The model revealed 
Table 1  Baseline 
characteristics
Data are presented as n (%) unless specified separately; FIGO, International Federation of Gynecology and 
Obstetrics; study sites could choose to document either FIGO or TNM stage, TNM documentation was 
translated into FIGO (according to NCCN guidelines version 3.2014 on epithelial ovarian cancer)
Treosulfan i.v. n = 128 Treosulfan p.o. n = 122
Age in years at therapy start [median (range)] 63 (32–84) 64 (29–87)
Karnofsky index
 100% 37 (28.9) 36 (29.5)
 90% 33 (25.8) 27 (22.1)
 80% 33 (25.8) 36 (29.5)
 ≤70% 12 (9.4) 11 (9.0)
 Not specified/missing 13 (10.2) 12 (9.8)
FIGO stage at initial diagnosis
 I 5 (3.9) 5 (4.1)
 II 5 (3.9) 2 (1.6)
 III 73 (57.0) 60 (49.2)
 IV 30 (23.4) 29 (23.8)
 Not specified 15 (11.7) 26 (21.3)
Relapse-free interval after last platinum-containing 
therapy
 <6 months 68 (53.1) 65 (53.3)
 >6 months 60 (46.9) 57 (46.7)
Previous therapies
 Surgery (initial) 127 (99.2) 122 (100.0)
 Radiotherapy 9 (7.0) 7 (5.7)
Number of previous chemotherapy lines [median 
(range)]
2 (1–7) 2 (1–6)
 2 previous lines 81 (63.3) 80 (65.6)
 ≥2 previous lines 47 (36.7) 42 (34.4)
Concomitant diseases 3 (1–13) 3 (1–11)
 Gastrointestinal disorders 62 (48.4) 68 (55.3)
 Vascular disorders 63 (49.2) 62 (50.4)
  Hypertension 42 (32.8) 49 (39.8)
  Thromboembolism 12 (9.4) 7 (5.7)
 Metabolism/nutrition and endocrine disorders 59 (46.1) 62 (50.4)
  Diabetes 8 (6.3) 11 (8.9)
 Respiratory disorders 28 (21.9) 23 (18.7)
  Thromboembolism 5 (3.9) 6 (4.9)
 Cardiac disorders 12 (9.4) 20 (16.3)
  Cardiac failure 4 (3.1) 4 (3.3)
  Coronary artery disease 2 (1.6) 3 (2.4)
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significant differences for the following subgroups: Plat-
inum-sensitive patients showed a higher CBR (47.9% vs. 
31.6; p = 0.003) (S1 A) and developed a longer TTP (5.0 
vs. 2.8 months; p < 0.0001) (Fig. 2b and S1 B) compared to 
platinum-resistant patients. In the subgroup of Karnofsky 
index, the model revealed a significant longer TTP and OS 
for patients with a Karnofsky index ≥90 (TTP: 4.3 vs. 3.0, 
p = 0.039 and OS: 15.1 vs. 8.6, p < 0.0001) (S1 B, C). For 
platinum-sensitivity, no differences in OS were observed. 
The model did not show significant differences for any 
efficacy parameter for the subgroup of number of previous 
therapy lines and the subgroup of route of administration.
58% of patients received at least one further therapy 
after completion of study therapy. 11.6% of subsequent 
therapies were platinum based.
Quality of life/patient reported outcome
Questionnaire compliance was comparable in both treat-
ment arms. Baseline questionnaires were available for 
Table 2  Hematological and non-hematological toxicities all grades, highest grade per patient
Data are presented as n (%), adverse events were graded according to the National Cancer Institute Common Toxicity Criteria version 2.0
* Events occurring with a frequency >5% in any grade are listed
Treosulfan i.v. (n = 128) Treosulfan p.o. (n = 122)
Grade 1 Grade 2 Grade 3 Grade 4 Total Grade 1 Grade 2 Grade 3 Grade 4 Total
Patients with any adverse event 116 (90.6) 112 (91.8)
Patients with SAE 32 (25.0) 37 (30.3)
Hematological toxicities
 Blood/bone marrow 10 (7.8) 26 (20.3) 15 (11.7) 1 (0.8) 52 (40.6) 6 (4.9) 15 (12.3) 21 (17.2) 6 (4.9) 48 (39.3)
  Leukocytes (total WBC)* 2 (1.6) 16 (12.5) 4 (3.1) 1 (0.8) 23 (18.0) 2 (1.6) 13 (10.7) 18 (14.8) – 33 (27.0)
  Platelets 11 (8.6) 5 (3.9) 8 (6.2) – 24 (18.8) 8 (6.6) 5 (4.1) 8 (6.6) 2 (1.6) 23 (18.9)
  Hemoglobin 6 (4.7) 17 (13.3) 4 (3.1) – 27 (21.1) 1 (0.8) 9 (7.4) 3 (2.5) 2 (1.6) 15 (12.3)
Gastrointestinal toxicities
 Gastrointestinal 30 (23.4) 26 (20.3) 14 (10.9) 9 (7.0) 81 (63.3) 31 (25.4) 23 (18.9) 17 (13.9) 5 (4.1) 76 (62.3)
  Nausea 27 (21.1) 16 (12.5) 2 (1.6) – 46 (35.9) 30 (24.6) 5 (4.1) 4 (3.3) – 39 (32.0)
  Vomiting 7 (5.5) 15 (11.7) 3 (2.3) – 25 (19.5) 8 (6.6) 16 (13.1) 2 (1.6) 1 (0.8) 27 (22.1)
  Constipation 14 (10.9) 8 (6.2) 1 (0.8) 1 (0.8) 25 (19.5) 11 (9.0) 6 (4.9) 2 (1.6) – 19 (15.6)
  Diarrhea 11 (8.6) 4 (3.1) – – 16 (12.5) 15 (12.3 4 (3.3) – – 19 (15.6)
  Ileus – – 9 (7.0) 9 (7.0) 18 (14.0) – – 6 (4.9) 4 (3.3) 10 (8.2)
  Stomatitis/pharyngitis 3 (2.3) 4 (3.1) – – 7 (5.5) 5 (4.1) – – – 5 (4.1)
Other toxicities
 Fatigue 24 (18.8) 13 (10.2) 1 (0.8) – 38 (29.7) 24 (19.7) 9 (7.4) 3 (2.5) – 36 (29.5)
 Pain 24 (18.8) 23 (18.0) 3 (2.3) – 50 (39.1) 24 (19.7) 17 (13.9) 4 (3.3) – 45 (36.9)
  Abdominal pain or cramping 12 (9.4) 7 (5.5) 2 (1.6) – 21 (16.4) 18 (14.8) 7 (5.7) 2 (1.6) – 27 (22.1)
  Arthralgia 4 (3.1) 3 (2.3) – – 7 (5.5) 4 (3.3) 3 (2.5) – – 7 (5.7)
  Headache 5 (3.9) 1 (0.8) – – 6 (4.7) 5 (4.1) 2 (1.6) – – 7 (5.7)
  Myalgia 6 (4.7) 2 (1.6) – – 8 (6.2) 2 (1.6) – – – 2 (1.6)
 Dermatology/skin 21 (16.4) 4 (3.1) 1 (0.8) – 26 (20.3) 18 (14.8) 5 (4.1) 1 (0.8) – 24 (19.7)
  Alopecia 8 (6.2) 1 (0.8) – – 9 (7.0) 10 (8.2) – – – 10 (8.2)
 Pulmonary 5 (3.9) 15 (11.7) 4 (3.1) – 24 (18.8) 4 (3.3) 17 (13.9) 4 (3.3) 1 (0.8) 26 (21.3)
  Dyspnea – 12 (9.4) 3 (2.3) – 15 (11.7) – 16 (13.1) 1 (0.8) – 17 (13.9)
 Neurology 21 (16.4) 4 (3.1) 4 (3.1) 1 (0.8) 30 (23.4) 14 (11.5) 5 (4.1) – – 19 (15.6)
  Neuropathy sensory 9 (7.0) – – – 9 (7.0) 8 (6.6) 3 (2.5) – – 11 (9.0)
 Infection/febrile neutropenia 6 (4.7) 12 (9.4) 3 (2.3) 1 (0.8) 22 (17.2) 4 (3.3) 6 (4.9) 6 (4.9) – 16 (13.1)
  Infection without neutro-
penia
4 (3.1) 9 (7.0) – – 13 (10.2) 3 (2.5) 6 (4.9) 2 (1.6) – 11 (9.0)
 Renal/genitourinary 4 (3.1) 7 (5.5) 1 (0.8) – 12 (9.4) 6 (4.9) 4 (3.3) 4 (3.3) 1 (0.8) 15 (12.3)
 Cardiovascular (general) 6 (4.7) 2 (1.6) 2 (1.6) 1 (0.8) 11 (8.6) 3 (2.5) 5 (4.1) 2 (1.6) 2 (1.6) 12 (9.8)
 Musculoskeletal 3 (2.3) 5 (3.9) – – 8 (6.2) 4 (3.3) 2 (1.6) 2 (1.6) 1 (0.8) 9 (7.4)
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81.3% of patients in the i.v. treatment arm and from 82.0% 
of patients in the p.o. treatment arm. Significant differences 
in global health, fatigue as well as in gastrointestinal and 
hematological subscales were detected neither between the 
treatment arms nor over time during the first 6 months of 
treatment (S2 A-F).
Discussion
As most ovarian cancer patients suffer from relapse, treat-
ment of recurrent ovarian cancer remains a major issue 
in the clinical management of ovarian cancer. Stand-
ard chemotherapies are either platinum-based regimens 
in combination with agents such as liposomal doxoru-
bicin, gemcitabin, paclitaxel and bevacizumab or olapa-
rib (Pujade-Lauraine et al. 2010; Aghajanian et al. 2012; 
Oza et al. 2015) or non-platinum-based regimens such as 
liposomal doxorubicin, paclitaxel, topotecan and gemcit-
abine combined with targeted therapies like bevacizumab 
(Meier et al. 2009; Monk et al. 2010; Pujade-Lauraine 
et al. 2014; Sehouli et al. 2008). In general, patients with 
more than two previous lines of chemotherapy have been 
excluded from these trials, so translation of the results on 
heavily pretreated patients is limited. Various randomized 
and non-randomized trials have demonstrated activity in 
recurrent ovarian cancer for the alkylating agent treosul-
fan (Gropp et al. 1998; Köpf-Meier and Sass 1996; Meier 
et al. 2009). For patients in the palliative setting of recur-
rent ovarian cancer the maintenance of quality of life is, 
beside the maintenance of tumor control, the main goal of 
treatment. To sustain a maximum of flexibility, the choice 
of the route of administration is an important aspect in eve-
ryday life. Liu et al. (1997) assessed patient preferences 
for oral versus intravenous palliative chemotherapy using 
a structured interviewer-administered questionnaire. Major 
reasons for a clear preference for oral chemotherapy (92 of 
103 patients) were convenience, problems with i.v. access 
and a better chemotherapy-taking environment outside the 
clinic. Nevertheless, despite their initial clear preference 
for oral chemotherapy patients were not willing to sacrifice 
efficacy for their preference. In contrast, the NOGGO study 
group has investigated the preference of elderly patients 
≥65 years regarding p.o. or i.v. treosulfan for the treat-
ment of relapsed ovarian cancer in 123 patients and showed 
a clear preference for the i.v. administration of treosulfan. 
The main reasons for this decision were the hope for less 
gastrointestinal toxicities, a better control of drug deliv-
ery and the assumption, that i.v. therapy is more effective. 
Therefore, in terms of different patient populations and 
their preferences the availability of different formulations 
might be worthwhile, if efficacy and safety are comparable. 
Here, we present the final results of our randomized study 
comparing p.o. and i.v. treosulfan to increase information 
on safety and efficacy of both formulations. Previous data 
especially on p.o. treosulfan were mainly based on a low 
number of patients. Detailed safety data were scarce. To 
our knowledge, our study is the largest performed in ovar-
ian cancer comparing i.v. versus p.o. treosulfan in terms of 
efficacy and safety.
Despite the heavy pretreatment of the patients, treosul-
fan therapy was well tolerated in both treatment arms. The 
majority of toxicities were grade I or II. Most frequently 
observed hematological toxicities of grade III/IV in both 
treatment arms were leucopenia (9.2%; 3.9% in the i.v. arm 
and 14.8% in the p.o. arm) and thrombocytopenia (7.2%; 
6.2% in the i.v. arm and 8.2% in the p.o. arm). Compared 
to the i.v. arm, a statistically significant higher number of 
grade III/IV leucopenia occurred in the p.o. arm in our 
study. This number might explain the higher number of 
treatment discontinuations in this treatment arm due to 
unacceptable toxicity. However, only one case of febrile 
neutropenia in the p.o. treatment arm was reported. Most 
frequent documented gastrointestinal toxicity grade III/IV 
was ileus (11.2%; 14.0% in the i.v. arm and 8.2% in the 
p.o. arm). Toxicities during therapy with intravenous treo-
sulfan had been reported in several previous studies (Meier 
et al. 2009; Mahner et al. 2012). However, safety data on 
therapy with oral treosulfan are rare. Keldsen et al. (1998) 
reported that oral treosulfan treatment is well tolerated as 
Table 3  Response evaluation
Best response per patient. Data are presented as n (%)
CBR Clinical benefit rate; CR Complete response; PR Partial response; NC No change; PD Progressive 
disease; NE Not evaluable
CBR (95% CI) Treosulfan i.v. n = 128 Treosulfan p.o. n = 122 Total
53 (41.4 (32.9 – 50.5)) 45 (36.9 (28.5 – 46.1)) 98 (39.2 (33.2 – 45.6))
CR 5 (3.9) 1 (0.8) 6 (2.4)
PR 16 (12.5) 15 (12.3) 31 (12.4)
NC 32 (25.0) 29 (23.8) 61 (24.4)
PD 58 (45.3) 56 (45.9) 114 (45.6)
NE 17 (13.3) 21 (17.2) 38 (15.2)
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second-line treatment for platinum-resistant cancer in a 
patient collective with a median age of 61 years. Meden 
et al. (1997) investigated toxicities of oral treosulfan in 
patients receiving treosulfan as maintenance therapy after 
first-line chemotherapy. As in our study, in total leuco-
penia and thrombocytopenia were among the most fre-
quently reported grade III/IV toxicities. The frequency of 
observed thrombocytopenia (7.2%) is comparable with 
those published by Meier et al. (2009) (7.5%) and Mahner 
et al. (2012) (4.0%). In contrast, the frequency of leucope-
nia observed in the treosulfan i.v. arm in our study (3.9%) 
is much lower than that reported by Meier et al. (2009) 
(18.3%) and Mahner et al. (2012) (12.0%). Additionally 
neutropenia was far less frequently observed in our study 
(0.8%) than by Meier et al. (2009) (14.4%) and Mahner 
et al. (2012) (8.0%). Possible explanations for this differ-
ence in toxicity rates could be that Meier et al. used a more 
dose-dense treatment regimen (7000 mg/m2 d1 q3w), but 
patients in these study were less heavily pretreated.
No significant differences in disease control rate (41.4% 
in the i.v. arm and 36.9% in the p.o. arm), time to progres-
sion (3.7 months in the i.v. arm and 3.5 months in the p.o. 
arm) or overall survival (13.6 months in the i.v. arm and 
10.4 months in the p.o. arm) were observed in our study. 
In comparison to data from a first-line study by Reed et al. 
(2006) and a second-line study by Gropp et al. (1998) on 
intravenous treosulfan, disease control (Reed: 50.0%; 
Gropp: 53.0%) and time to progression (Reed: 5.0 months) 
are slightly lower in our study. However, in our study we 
were dealing with patients with many concomitant dis-
eases in more advanced treatment lines that were older than 
patients investigated in the second-line study by Gropp 
et al. In our study, a nonsignificant trend toward a pro-
longed survival in the i.v. arm could be observed (13.6 vs. 
10.4 months). But this comparison is due the very limited 
methodological limitations only hypothesis generating.
Interestingly the number of previous treatment lines 
(two or less vs. more than two) did not have an impact 
on any of the efficacy parameters. This indicates that also 
heavily pretreated patients benefit from treosulfan treat-
ment to the same extent. A recent large study of the Ger-
man AGO stated that patients with relapsed ovarian cancer 
seem to benefit form subsequent relapse treatment at the 
second to fourth recurrence (Hanker et al. 2012).
Due to several amendments throughout the entire term 
of the study, different definitions of how to count previous 
treatment lines were used. As we merged induction and re-
induction therapy for analyses, there might be an underesti-
mation of previous therapy lines. This has to be considered 
when comparing our results with other studies.
When comparing survival data of platinum-resistant 
patients in our study to data from a large phase III study 
(Pujade-Lauriane et al. 2014) in which ovarian cancer 
Fig. 2  Time to progression (TTP) (a) By treatment arm (b). By plati-
num sensitivity and treatment arm (c) By number of previous therapy 
lines and treatment arm. HR Hazard ratio
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patients are treated with chemotherapy ± bevacizumab in 
second and third line, overall survival of platinum-resistant 
patients treated with treosulfan in our study is within the 
same range as survival of platinum-resistant patients treated 
with chemotherapy only (11.9 vs. 13.3 months). Given the 
mild toxicity profile of treosulfan therapy and similar effect 
on disease survival, the treosulfan therapy seems to be an 
attractive option for treatment of the platinum-resistant 
recurrent disease.
The quality of life analysis did not show any significant 
differences in global health score or in selected subscales 
between the two treatment arms. In both arms a nonsignifi-
cant slight improvement in quality of life during therapy 
could be observed. However, due to many patients experi-
encing early progressive disease during therapy, the avail-
able data set shows a high dropout rate, limiting the mean-
ingfulness of the analysis.
In summary, observed toxicities with oral and intrave-
nous treosulfan were in the same range as in previous stud-
ies. Interestingly a higher number of leucopenia grade III/
IV occurred in the p.o. treatment arm. Apart from this, no 
additional significant differences in toxicity were observed 
between the treatment arms. CBR, TTP and OS data were 
comparable to previously reported data and did not differ 
significantly between both treatment arms. Heavy pretreat-
ment did not detract from the benefit of treosulfan treatment. 
Patients with ROC who have frequently more gastrointesti-
nal symptoms and polypharmacy due to co-morbidities may 
tolerate an i.v. treatment better. In a synopsis of efficacy and 
safety outcomes, there might be an advantage for i.v. appli-
cation form for treosulfan treatment. Still, treatment with 
oral treosulfan remains a considerable option.
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